New cream could stop scarring hair loss in its tracks

NCT ID NCT07487948

First seen Mar 27, 2026 · Last updated Jun 14, 2026 · Updated 10 times

Summary

This study tests a cream called delgocitinib on adults with two types of scarring hair loss (LPP and CCCA). The goal is to see if it is safe and how it affects certain markers in the scalp. About 30 people will use the cream twice a day for 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.